1,3-Dibenzyl-5-Fluorouracil Prevents Ovariectomy-Induced Bone Loss by Suppressing Osteoclast Differentiation

• Published in: Immune network Vol. 22; no. 5; pp. 119 - 130
• Main Authors: Jeon, Hyoeun, Yu, Jungeun, Hwang, Jung Me, Park, Hye-Won, Yu, Jiyeon, Lee, Zee-Won, Kim, Taesoo, Rho, Jaerang
• Format: Journal Article
• Language: English
• Published: 대한면역학회 01-10-2022; The Korean Association of Immunologists
• Subjects: Brief Communication; Osteoclastogenesis; Osteoporosis; Osteoclasts; 1,3-Dibenzyl-5-fluorouracil; Ovariectomy
• ISSN: 1598-2629; 2092-6685
• DOI: 10.4110/in.2022.22.e43

Osteoclasts (OCs) are clinically important cells that resorb bone matrix. Accelerated bone destruction by OCs is closely linked to the development of metabolic bone diseases. In this study, we screened novel chemical inhibitors targeting OC differentiation to identify drug candidates for metabolic bone diseases. We identified that 1,3-dibenzyl-5-fluorouracil, also named OCI-101, is a novel inhibitor of osteoclastogenesis. The formation of multinucleated OCs is reduced by treatment with OCI-101 in a dose-dependent manner. OCI-101 inhibited the expression of OC markers via downregulation of receptor activator of NF-κB ligand and M-CSF signaling pathways. Finally, we showed that OCI-101 prevents ovariectomy-induced bone loss by suppressing OC differentiation in mice. Hence, these results demonstrated that OCI-101 is a good drug candidate for treating metabolic bone diseases.